Indian study finds big drop in COVID antibodies within four months of vaccination
Reuters
Published Sep 14, 2021 06:24AM ET
By Jatindra Dash and Krishna N. Das
BHUBANESWAR, India (Reuters) - A study https://www.researchsquare.com/article/rs-888762/v1 of 614 fully vaccinated health workers in India found a "significant" drop in their COVID-fighting antibodies within four months of the first shot.
The findings could help the Indian government decide whether to provide booster doses as some Western countries reuters.com/world/uk/uk-pm-johnson-set-out-covid-19-booster-strategy-under-winter-plan-2021-09-13 have done.
Waning antibodies do not necessarily mean that immunised people lose their ability to counter the disease, as the body's memory cells may still kick in to offer substantial protection, said the director of a state-run institute that did the study.
"After six months, we should be able to tell you more clearly whether and when a booster would be needed," Sanghamitra Pati of the Regional Medical Research Centre, based in the eastern city of Bhubaneswar, told Reuters on Tuesday.
"And we would urge similar studies in different areas for pan-India data."
British researchers said last month that protection offered by two doses of the Pfizer/BioNTech and the AstraZeneca (NASDAQ:AZN) vaccines begins to fade within six months https://www.reuters.com/business/healthcare-pharmaceuticals/covid-jab-protection-wanes-within-six-months-uk-researchers-2021-08-25.
The Indian study, published in the Research Square pre-print platform but yet to be peer reviewed, is one of the first such done in the country involving its main two vaccines - Covishield, a licensed version of the AstraZeneca shot, and domestically developed Covaxin.
Health officials say though they are studying the evolving science on booster doses, the priority is to fully immunise India's 944 million adults. More than 60% of them have received at least one dose and 19% the required two doses.
COVID cases and deaths in India have come down sharply since a peak of more than 400,000 infections in early May. India has reported 33.29 million cases in total and 443,213 deaths.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.